RBN-2397 |
| カタログ番号GC39504 |
RBN-2397は強力な、種を越えた、経口的に活性なNAD+競合的PARP7阻害剤です(IC50<3 nM)。 RBN-2397 は PARP7 に選択的に結合し (Kd=0.001 μM)、IFN シグナル伝達を回復します。 RBN-2397 は、進行性または転移性固形腫瘍の研究の可能性を秘めています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2381037-82-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores interferon (Type I) signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].
[1]. RBN-2397-Inhibiting PARP7, a Key monoPARP Cancer Dependency [2]. Melissa Vasbinder, et al. RBN-2397: A First-in-Class PARP7 Inhibitor Targetinga Newly Discovered Cancer Vulnerability in Stress-Signaling Pathways.
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *